JP2022534724A5 - - Google Patents
Info
- Publication number
- JP2022534724A5 JP2022534724A5 JP2021570319A JP2021570319A JP2022534724A5 JP 2022534724 A5 JP2022534724 A5 JP 2022534724A5 JP 2021570319 A JP2021570319 A JP 2021570319A JP 2021570319 A JP2021570319 A JP 2021570319A JP 2022534724 A5 JP2022534724 A5 JP 2022534724A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- prg4
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856514P | 2019-06-03 | 2019-06-03 | |
| US62/856,514 | 2019-06-03 | ||
| US202063013427P | 2020-04-21 | 2020-04-21 | |
| US63/013,427 | 2020-04-21 | ||
| PCT/US2020/035841 WO2020247440A1 (en) | 2019-06-03 | 2020-06-03 | Use of prg4 to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534724A JP2022534724A (ja) | 2022-08-03 |
| JP2022534724A5 true JP2022534724A5 (enExample) | 2023-06-07 |
Family
ID=73652433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570319A Pending JP2022534724A (ja) | 2019-06-03 | 2020-06-03 | がんを治療するためのｐｒｇ４の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220332839A1 (enExample) |
| EP (1) | EP3976085A4 (enExample) |
| JP (1) | JP2022534724A (enExample) |
| CN (1) | CN114173805A (enExample) |
| WO (1) | WO2020247440A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000022636A1 (it) * | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma” |
| KR102763607B1 (ko) * | 2021-10-05 | 2025-02-07 | 주식회사 인게니움테라퓨틱스 | 자연살해 세포의 활성 향상용 조성물 |
| CN115125207B (zh) * | 2022-08-01 | 2023-05-02 | 威海见生生物技术有限公司 | 一种诱导干细胞体外定向分化的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015060935A1 (en) * | 2013-10-22 | 2015-04-30 | Lubris, Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
| AU2014354859B2 (en) * | 2013-11-26 | 2020-04-09 | Lubris Llc | Compositions and methods for inhibiting intercellular interactions |
| AU2016211694B2 (en) * | 2015-01-26 | 2021-11-11 | Lubris Llc | Use of PRG4 as an anti-inflammatory agent |
-
2020
- 2020-06-03 US US17/596,066 patent/US20220332839A1/en not_active Abandoned
- 2020-06-03 JP JP2021570319A patent/JP2022534724A/ja active Pending
- 2020-06-03 WO PCT/US2020/035841 patent/WO2020247440A1/en not_active Ceased
- 2020-06-03 CN CN202080049571.8A patent/CN114173805A/zh active Pending
- 2020-06-03 EP EP20818641.1A patent/EP3976085A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534724A5 (enExample) | ||
| EP3197493B1 (en) | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent | |
| JP2010533206A5 (enExample) | ||
| HRP20150143T1 (hr) | Imunokonjugati koji ciljaju na cd138 i njihova upotreba | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| HRP20201046T1 (hr) | Sastavi i metode za inhibitivnu aktivnost arginase | |
| JP2016539087A5 (enExample) | ||
| JP2009544728A5 (enExample) | ||
| JP2006507308A5 (enExample) | ||
| JP2021528496A5 (enExample) | ||
| RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
| JP2022507025A5 (enExample) | ||
| JP2023533937A5 (enExample) | ||
| Usmani et al. | Novel drug combinations for the management of relapsed/refractory multiple myeloma | |
| JP2018535206A5 (enExample) | ||
| AU2024216395A1 (en) | Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy | |
| JP2022548145A5 (enExample) | ||
| CN115461079A (zh) | 用于治疗肾癌的联用药物 | |
| US20100008980A1 (en) | Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer | |
| Ryu et al. | A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy | |
| JP2021534091A5 (enExample) | ||
| EP4565239A1 (en) | Combination therapy of cdk7 inhibitors with other anti-cancer therapies | |
| CN103491977A (zh) | 癌症的组合治疗 | |
| Witkowska et al. | Development of Anti-CD20 antigen-targeting therapies for B-cell lymphoproliferative malignancies-the state of the art | |
| CA3223395C (en) | Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy |